Essential Partners’s Praxis Precision Medicines PRAX Stock Holding History

Essential Partners’s Portfolio PRAX Stock Details PRAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$6.41K	Buy	22 +1	+5%	+$331	﹤0.01%	1400
2026 Q2	$7.03K	Buy	21 +17	+425%	+$5.38K	﹤0.01%	1376
2026 Q1	$1.29K	Hold	4	–	–	﹤0.01%	2160
2025 Q4	$1.18K	Buy	4 +3	+300%	+$559	﹤0.01%	1978
2025 Q3	$53	Hold	1	–	–	﹤0.01%	2562
2025 Q2	$42	Buy	+1	New	+$38	﹤0.01%	2163

Other funds holding PRAX

Mutual of America Capital Management New York $10.1B AUM 33.74% 1-Year Est. Return

Nisa Investment Advisors St. Louis, Missouri $34.7B AUM 25.93% 1-Year Est. Return

Atria Investments Charlotte, North Carolina $10.3B AUM 19.62% 1-Year Est. Return

Inspire Investing Meridian, Idaho $2.37B AUM 29.82% 1-Year Est. Return

AssetMark Inc Concord, California $59.5B AUM 15.92% 1-Year Est. Return

Net Worth Advisory Group Sandy, Utah $397M AUM 23.64% 1-Year Est. Return

Eagle Bay Advisors New York $137M AUM 18.51% 1-Year Est. Return

Abel Hall LLC Baton Rouge, Louisiana $556M AUM 43.18% 1-Year Est. Return

Sterling Capital Management Charlotte, North Carolina $4.92B AUM 24.73% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return

Essential Partners's PRAX Position: Q3 2026 in Review

Essential Partners increased its Praxis Precision Medicines (PRAX) stake by 4.8% in Q3 2026, buying an estimated $331 and bringing the position to 22 shares worth $6.41K. The position accounts for ﹤0.01% of the portfolio, ranked #1400.

Essential Partners first reported a position in PRAX in Q2 2025 and has held it in 6 quarters since. The position peaked at $7.03K in Q2 2026. 29 funds tracked by Wall St. Rank hold PRAX as of Q3 2026.

Essential Partners held 22 shares of Praxis Precision Medicines worth $6.41K as of Q3 2026.
Essential Partners bought 1 Praxis Precision Medicines share in Q3 2026, an estimated $331.
Praxis Precision Medicines made up ﹤0.01% of Essential Partners's portfolio in Q3 2026, its #1400 holding.
Essential Partners first reported a position in Praxis Precision Medicines in Q2 2025 and has held it in 6 quarters since.
Essential Partners's Praxis Precision Medicines position peaked at $7.03K in Q2 2026.
29 funds tracked by Wall St. Rank held Praxis Precision Medicines as of Q3 2026.

Based on Essential Partners's 13F filing for Q3 2026, filed 14 Oct 2026.